Evidence map›Paper›PMID 37443366›Full record

ArticleNPJ vaccines2023

Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens.

Gregory M Martin, Rebecca A Russell, Philip Mundsperger, Scarlett Harris, Lu Jovanoska, Luiza Farache Trajano, Torben Schiffner, Katalin Fabian, Monica Tolazzi, Gabriella Scarlatti and 12 more

Abstract read
In one paragraph

Article in NPJ vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Gregory M Martin *Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA. gmartin@scripps.edu.
Rebecca A Russell *The Sir William Dunn School of Pathology, The University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-6517-6483
Philip MundspergerPolymun Scientific Immunbiologische Forschung GmbH, Klosterneuburg, Austria.ORCID http://orcid.org/0000-0002-9095-5657
Scarlett HarrisThe Sir William Dunn School of Pathology, The University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-5717-4093
Lu JovanoskaThe Sir William Dunn School of Pathology, The University of Oxford, Oxford, UK.
Luiza Farache TrajanoThe Sir William Dunn School of Pathology, The University of Oxford, Oxford, UK.
Torben SchiffnerThe Sir William Dunn School of Pathology, The University of Oxford, Oxford, UK.
Katalin FabianDepartment of Immunology, National Food Chain Safety Office, Directorate of Veterinary Medicinal Products, Budapest, Hungary.
Monica TolazziViral Evolution and Transmission Unit, Division of Immunology, Transplantation, and Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy.
Gabriella ScarlattiViral Evolution and Transmission Unit, Division of Immunology, Transplantation, and Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy.ORCID http://orcid.org/0000-0003-2316-2689
Leon McFarlaneImperial College London, Department of Medicine, Division of Infectious Diseases, Section of Virology, Norfolk Place, London, W2 1PG, UK.
Hannah CheesemanImperial College London, Department of Medicine, Division of Infectious Diseases, Section of Virology, Norfolk Place, London, W2 1PG, UK.ORCID http://orcid.org/0000-0001-9044-1341
Yoann AldonImperial College London, Department of Medicine, Division of Infectious Diseases, Section of Virology, Norfolk Place, London, W2 1PG, UK.ORCID http://orcid.org/0000-0001-9831-9391
Edith E SchermerDepartment of Medical Microbiology, Academic Medical Centre University of Amsterdam, Amsterdam, The Netherlands.
Marielle BreemenDepartment of Medical Microbiology, Academic Medical Centre University of Amsterdam, Amsterdam, The Netherlands.
Kwinten SliepenDepartment of Medical Microbiology, Academic Medical Centre University of Amsterdam, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0003-1414-0648
Dietmar KatingerPolymun Scientific Immunbiologische Forschung GmbH, Klosterneuburg, Austria.ORCID http://orcid.org/0000-0002-0536-3148
Renate KunertDepartment of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria.ORCID http://orcid.org/0000-0002-3397-3621
Rogier W SandersDepartment of Medical Microbiology, Academic Medical Centre University of Amsterdam, Amsterdam, The Netherlands.
Robin ShattockImperial College London, Department of Medicine, Division of Infectious Diseases, Section of Virology, Norfolk Place, London, W2 1PG, UK.ORCID http://orcid.org/0000-0002-4936-1718
Andrew B WardDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA. andrew@scripps.edu.ORCID http://orcid.org/0000-0001-7153-3769
Quentin J SattentauThe Sir William Dunn School of Pathology, The University of Oxford, Oxford, UK. quentin.sattentau@path.ox.ac.uk.ORCID http://orcid.org/0000-0001-7170-1937

Funding

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BAROUCH, DAN H. · 2012 to 2018
$131.5M
Medical Research Council G0000635NIAID NIH HHS UM1 AI100663NIAID NIH HHS UM1 AI144462
6 · The paper itself

Abstract

Chemical cross-linking is used to stabilize protein structures with additional benefits of pathogen and toxin inactivation for vaccine use, but its use has been restricted by the potential for local or global structural distortion. This is of particular importance when the protein in question requires a high degree of structural conservation for inducing a biological outcome such as the elicitation of antibodies to conformationally sensitive epitopes. The HIV-1 envelope glycoprotein (Env) trimer is metastable and shifts between different conformational states, complicating its use as a vaccine antigen. Here we have used the hetero-bifunctional zero-length reagent 1-Ethyl-3-(3-Dimethylaminopropyl)-Carbodiimide (EDC) to cross-link two soluble Env trimers, selected well-folded trimer species using antibody affinity, and transferred this process to good manufacturing practice (GMP) for experimental medicine use. Cross-linking enhanced trimer stability to biophysical and enzyme attack. Cryo-EM analysis revealed that cross-linking retained the overall structure with root-mean-square deviations (RMSDs) between unmodified and cross-linked Env trimers of 0.4-0.5 Å. Despite this negligible distortion of global trimer structure, we identified individual inter-subunit, intra-subunit, and intra-protomer cross-links. Antigenicity and immunogenicity of the trimers were selectively modified by cross-linking, with cross-linked ConS retaining bnAb binding more consistently than ConM. Thus, the EDC cross-linking process improves trimer stability whilst maintaining protein folding, and is readily transferred to GMP, consistent with the more general use of this approach in protein-based vaccine design.

Identifiers

PMID37443366
PMCPMC10345191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.